Payment overview · 2025
General Payments
$1,655.39
83 reported records · 14 companies
Healthcare provider profile · identity verified
Richard C. Lock, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1558334219
Verified facts
What the public records show
CMS Open Payments records show Richard C. Lock, M.D. received $1,655.39 in general payments during 2025 across 83 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $380.63 | 23.0% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $300.84 | 18.2% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $281.29 | 17.0% | 14 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $243.24 | 14.7% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $191.80 | 11.6% | 12 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.21 | 3.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.57 | 2.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.70 | 2.0% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $30.21 | 1.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.52 | 1.8% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.32 | 1.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.84 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.30 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.92 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,655.39 | 83 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $278.31 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $243.24 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $185.99 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $183.35 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $170.65 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $166.26 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $148.27 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $110.63 | 6 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $107.25 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $97.94 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $84.01 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.21 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.57 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.70 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $29.52 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 76 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 105 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 135 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
31 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
76 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
76 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
135 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1296 | 387 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1198 | 385 |
| Losartan Potassium | Losartan Potassium | 1004 | 305 |
| Amlodipine Besylate | Amlodipine Besylate | 848 | 259 |
| Metoprolol Succinate | Metoprolol Succinate | 809 | 239 |
| Levothyroxine Sodium | Levothyroxine Sodium | 753 | 202 |
| Metformin Hcl Er | Metformin Hcl | 738 | 228 |
| Tamsulosin Hcl | Tamsulosin Hcl | 597 | 196 |
| Tizanidine Hcl | Tizanidine Hcl | 516 | 173 |
| Pantoprazole Sodium | Pantoprazole Sodium | 425 | 139 |
| Gabapentin | Gabapentin | 359 | 120 |
| Lisinopril | Lisinopril | 340 | 103 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 294 | 93 |
| Diclofenac Sodium | Diclofenac Sodium | 272 | 77 |
| Omeprazole | Omeprazole | 272 | 83 |
| Famotidine | Famotidine | 271 | 92 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 266 | 83 |
| Clonazepam | Clonazepam | 260 | 49 |
| Tramadol Hcl | Tramadol Hcl | 251 | 54 |
| Furosemide | Furosemide | 240 | 82 |
| Simvastatin | Simvastatin | 238 | 76 |
| Alendronate Sodium | Alendronate Sodium | 233 | 76 |
| Hydralazine Hcl | Hydralazine Hcl | 230 | 80 |
| Carvedilol | Carvedilol | 227 | 73 |
| Donepezil Hcl | Donepezil Hcl | 224 | 84 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 224 | 110 |
| Allopurinol | Allopurinol | 214 | 67 |
| Metformin Hcl | Metformin Hcl | 213 | 68 |
| Glipizide Er | Glipizide | 204 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 202 | 66 |
| Clopidogrel | Clopidogrel Bisulfate | 195 | 60 |
| Alprazolam | Alprazolam | 191 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 190 | 70 |
| Clonidine Hcl | Clonidine Hcl | 189 | 68 |
| Finasteride | Finasteride | 187 | 63 |
| Meloxicam | Meloxicam | 175 | 64 |
| Atenolol | Atenolol | 169 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 168 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 156 | 57 |
| Nifedipine Er | Nifedipine | 154 | 47 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 151 | 59 |
| Potassium Chloride | Potassium Chloride | 151 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 150 | 47 |
| Sertraline Hcl | Sertraline Hcl | 143 | 40 |
| Meclizine Hcl | Meclizine Hcl | 141 | 62 |
| Azithromycin | Azithromycin | 140 | 118 |
| Ozempic | Semaglutide | 135 | 30 |
| Eliquis | Apixaban | 130 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 123 | 106 |
| Lorazepam | Lorazepam | 123 | 29 |
| Ezetimibe | Ezetimibe | 120 | 43 |
| Mirtazapine | Mirtazapine | 119 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 117 | 40 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 117 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 112 | 35 |
| Trazodone Hcl | Trazodone Hcl | 109 | 34 |
| Jardiance | Empagliflozin | 105 | 34 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 101 | 81 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 101 | 37 |
| Montelukast Sodium | Montelukast Sodium | 101 | 32 |
| Mupirocin | Mupirocin | 96 | 53 |
| Celecoxib | Celecoxib | 94 | 35 |
| Baclofen | Baclofen | 90 | 45 |
| Bupropion Xl | Bupropion Hcl | 90 | 27 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 86 | 43 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 79 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 32 |
| Dicyclomine Hcl | Dicyclomine Hcl | 76 | 39 |
| Farxiga | Dapagliflozin Propanediol | 76 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 22 |
| Glipizide | Glipizide | 75 | 26 |
| Mometasone Furoate | Mometasone Furoate | 74 | 38 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 72 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 68 | 24 |
| Irbesartan | Irbesartan | 65 | 20 |
| Valsartan | Valsartan | 65 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 21 |
| Diazepam | Diazepam | 63 | suppressed |
| Pregabalin | Pregabalin | 62 | 18 |
| Benazepril Hcl | Benazepril Hcl | 61 | 15 |
| Mounjaro | Tirzepatide | 61 | 15 |
| Fenofibrate | Fenofibrate | 59 | 19 |
| Nystatin | Nystatin | 59 | 32 |
| Buspirone Hcl | Buspirone Hcl | 57 | 12 |
| Memantine Hcl | Memantine Hcl | 57 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 14 |
| Ondansetron Odt | Ondansetron | 52 | 20 |
| Valacyclovir | Valacyclovir Hcl | 52 | 23 |
| Prednisone | Prednisone | 51 | 26 |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 46 | suppressed |
| Ramipril | Ramipril | 46 | 14 |
| Spironolactone | Spironolactone | 46 | 18 |
| Levetiracetam | Levetiracetam | 45 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 14 |
| Levofloxacin | Levofloxacin | 44 | 36 |
| Paxlovid | Nirmatrelvir/Ritonavir | 44 | 44 |
| Amoxicillin | Amoxicillin | 41 | 36 |
| Eszopiclone | Eszopiclone | 41 | suppressed |
| Glimepiride | Glimepiride | 41 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | 14 |
| Novolog Flexpen | Insulin Aspart | 39 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 37 | 12 |
| Methylprednisolone | Methylprednisolone | 37 | 30 |
| Synthroid | Levothyroxine Sodium | 36 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Sucralfate | Sucralfate | 34 | 13 |
| Torsemide | Torsemide | 34 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 32 | suppressed |
| Ketoconazole | Ketoconazole | 32 | 12 |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Entecavir | Entecavir | 31 | suppressed |
| Lidocaine | Lidocaine | 31 | suppressed |
| Prolia | Denosumab | 31 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Levoxyl | Levothyroxine Sodium | 30 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Colchicine | Colchicine | 29 | 12 |
| Breyna | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Clonidine | Clonidine | 26 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 25 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | 14 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Naproxen | Naproxen | 23 | 11 |
| Topiramate | Topiramate | 23 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 22 | 19 |
| Fluconazole | Fluconazole | 22 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 21 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Procto-Med Hc | Hydrocortisone | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 13 |
| Cephalexin | Cephalexin | 15 | 12 |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Oxazepam | Oxazepam | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Xiidra | Lifitegrast | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,655.39 · 83 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, FARXIGA, GVOKE HYPOPEN, JARDIANCE, KRYSTEXXA, MOUNJARO, NEXLETOL, NUZYRA, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error